Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Masi

Showing results (131-140 of 133) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 133 results.
NPJ Precision Oncology|April 10, 2026
The role of the molecular tumor board: learnings from the ROME trialP Marchetti, G Curigliano, C B Westphalen, et al.
ESMO Open|July 6, 2026
Cisplatin-gemcitabine-durvalumab reintroduction in advanced biliary tract cancer: a multinational real-world analysisS Camera, A Vogel, M Rimini, et al.
ESMO Open|October 8, 2022
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysisM Rimini, L Rimassa, K Ueshima, et al.
Pageof 14

Showing results (131-140 of 133) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 133 results.
NPJ Precision Oncology|April 10, 2026
The role of the molecular tumor board: learnings from the ROME trialP Marchetti, G Curigliano, C B Westphalen, et al.
ESMO Open|July 6, 2026
Cisplatin-gemcitabine-durvalumab reintroduction in advanced biliary tract cancer: a multinational real-world analysisS Camera, A Vogel, M Rimini, et al.
ESMO Open|October 8, 2022
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysisM Rimini, L Rimassa, K Ueshima, et al.
Pageof 14